The World Health Organization recommended using arthritis drugs Actemra from Roche and Kevzara from Sanofi with corticosteroids for Covid-19 patients after data from some 11,000 patients showed they cut the risk of death.

U.S. health regulators approved Roche’s arthritis drug Actemra for emergency use to treat hospitalized Covid-19 patients, giving an extra boost to a medicine that was already allowed to be administered on compassionate grounds.

Arrowhead Pharmaceuticals and Horizon Therapeutics announced a research and development collaboration to advance an RNA interference (RNAi) therapeutic for uncontrolled gout.

The U.S. Supreme Court on May 17 dashed Novartis AG’s hopes of launching a generic version of Amgen Inc.’s multibillion-dollar rheumatoid arthritis medicine Enbrel, declining to hear the company’s challenge to two patents on the drug.

The European Medicines Agency will conduct an accelerated review of Eli Lilly and Co.’s rheumatoid arthritis drug Olumiant for hospitalized Covid-19 patients getting oxygen, the EU agency said on April 29, as the search for treatment options continues.

Eli Lilly and Co. and Incyte Corp. said their rheumatoid arthritis drug baricitinib did not meet the main goal of preventing progression to mechanical ventilation in hospitalized Covid-19 patients under a late-stage study.

Pfizer Inc. said on April 7 the U.S. Food and Drug Administration extended the review of the company’s experimental atopic dermatitis drug by three months, the latest regulatory setback for a class of treatments known as JAK inhibitors.

A legal complaint was filed against Alvotech for the Icelandic pharmaceutical company’s alleged misappropriation of trade secrets involving the development of a generic version of AbbVie’s rheumatoid arthritis drug Humira.

The U.S. Food and Drug Administration extended the review period for expanded use of Abbvie Inc.’s rheumatoid arthritis drug Rinvoq by three months, citing the need for more time to assess the drug’s benefit-risk profile.

The U.S. Food and Drug Administration approved Genentech’s Actemra (tocilizumab) for slowing the rate of decline in pulmonary function in adults with systemic sclerosis-associated interstitial lung disease (SSc-ILD).